Sanofi dengue vaccine Dengvaxia has been approved by the European Commission

dengue fever (Dengue) is an acute insect-borne infection caused by the mosquito-borne transmission of the dengue virusClinical manifestations of high fever, headache, muscle, bone joint severe soreness, rash, bleeding tendency, lymph node swelling, white blood cell count reduction, platelet reduction, dengue fever is one of the leading causes of death among children in Southeast Asia, France'sPharmaceutical(http://giant Sanofi announced that thecompany(http://developed dengue vaccine Dengvaxia has been approved by the European Commission (EC)Dengvaxia is a four-price detoxification live vaccine for children aged 9-45 who have a record of dengue infection and are living in areas where dengue fever is endemic, and preventd dengue disease caused by all four serotypes of dengue virusin the United States,FDA(http://is prioritizing the review of Dengvaxia's Bioproduct Licensing Application (BLA) and will make a final review decision by May 1, 2019If approved, Dengvaxia would be the first and only medical prevention tool for dengue fever in the U.SmarketDengvaxia was approved by Mexico in December 2015 as the world's first approved dengue vaccine product (http:// To date, the vaccine has been approved by several dengue-endemic countries in Latin America and Asia